DTDaria G. Tolkacheva

Daria G. Tolkacheva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daria G. Tolkacheva has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term efficacy of netakimab in the treatment of radiographic axial spondyloarthritis: Results of a systematic review and simulated indirect comparisons

    by A. M. Lila, T. V. Dubinina, O. N. Mironenko, A. A. Lazarev, K. V. Sapozhnikov, K. A. Katilova, D. G. Tolkacheva, А. М. Лила, Т. В. Дубинина, О. Н. Мироненко, et al.

    The aim – to compare the long-term efficacy of netakimab with other registered drugs in the Russian Federation to treat radiographic axial spondyloarthritis over a period of up to 3 years. Materials and methods . A systematic literature search was conducted in PubMed and Embase databases. 19 publications evaluating the results of 11 clinical trials were selected. The simulated treatment comparison method according to NICE DSU TSD 18 (National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 18) recommendations was used for comparison. Age, sex, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), ASDAS (Ankylosing Spondylitis Disease Activity Score), C-reactive protein, disease duration since axial spondyloarthritis diagnosis, and HLA-B27 status were selected as confounding variables for adjustment. Results . Netakimab demonstrated superiority over all interleukin 17 and tumor necrosis factor α (TNF-α) inhibitors, as well as tofacitinib, on the main efficacy endpoints ASAS20 and ASAS40 (20% and 40% improvement according to the Assessment of SpondyloArthritis international Society criteria) over a period of up to 3 years. No superiority was detected compared to upadacitinib. Conclusion. Netakimab is one of the most superior therapeutic option among available biologics for long-term treatment of active axial spondyloarthritis. Using netakimab as the first-line or second-line therapy allows achieving treatment goals with the highest probability. The results are useful for evidence-based clinical decision-making when choosing biological therapy considering patient profile and can be used for planning treatment strategy after TNF-α inhibitor failure.

  • Open Access

    Comparative efficacy and safety of prolgolimab and nivolumab in first-line therapy for metastatic or unresectable melanoma: a systematic review, matching-adjusted indirect comparison, and cost-effectiveness analysis

    by I. A. Utyashev, I. V. Myslevtsev, O. N. Mironenko, V. D. Batorova, K. A. Katilova, K. V. Sapozhnikov, N. A. Sableva, A. A. Lazarev, D. G. Tolkacheva

    Background . Metastatic and unresectable cutaneous melanoma (MM/uRCM) is an aggressive malignancy associated with high mortality due to its pronounced metastatic potential. Immune checkpoint inhibitors are used to treat MM/uRCM in the Russian Federation. These inhibitors include nivolumab and prolgolimab, which block the programmed cell death 1 (PD-1) receptor. However, there are no direct comparative data on their clinical and economic efficacy and safety as monotherapy, which complicates optimal therapeutic decision-making. Objective : To evaluate the clinical efficacy and safety of prolgolimab versus nivolumab in MM/uRCM treatment and to conduct cost-effectiveness analysis based on data obtained. Material and methods. A systematic literature search was conducted in the Embase and PubMed/MEDLINE databases, which identified four clinical trials of prolgolimab and nivolumab in first-line therapy for MM/uRCM. The results were used to perform a matchingadjusted indirect comparison (MAIC) without an anchor. Cox regression and logistic regression were applied for the efficacy and safety analyses, respectively. A cost minimization analysis was carried out using the weight characteristics of 743 Russian patients with MM/uRCM. The analysis only considered the costs of drug therapy. Additionally, the costs of treatment with comparator drugs were evaluated in real-world clinical setting, taking into account therapy discontinuation due to disease progression or patient death. A budget impact analysis was performed for 10 patients with MM/uRCM. Results . In MAIC, the prolgolimab monotherapy showed no statistically significant differences in overall survival compared to nivolumab after population balancing: hazard ratio (HR) 0.84 (95% confidence interval (CI) 0.47–1.50; p=0.557) in CheckMate 067 trial population; HR 0.89 (95% CI 0.53–1.49; p=0.649) in RELATIVITY-047 trial population. Similarly, for progression-free survival: HR 1.14 (95% CI 0.77–1.70; p=0.511) for CheckMate 067; HR 1.07 (95% CI 0.77–1.48; p=0.683) for RELATIVITY-047. Based on cost minimization analysis results, weighted average annual drug therapy costs for the Russian patient population were 3.98 million rubles for prolgolimab, compared to 5.33 million rubles for nivolumab (34% higher). First-year therapy costs accounting for gradual discontinuation due to progression and death were 2.39 million rubles for prolgolimab versus 3.2 million rubles for nivolumab (difference: 809,559 rubles; 34%). On a five-year horizon, total drug therapy costs were 6.16 million rubles for prolgolimab and 8.25 million rubles for nivolumab. Budget impact analysis revealed a difference in therapy costs for 10 patients with MM/uRCM over a 1-year and 5-year horizons of 13.47 and 20.84 million rubles, respectively. Due to the cost difference, an additional three patients can be treated within the analyzed timeframe. Conclusion . Prolgolimab monotherapy demonstrated no statistically significant differences in overall survival or progression-free survival compared with nivolumab in MAIC. Given its comparable clinical efficacy and lower cost per treatment course, prolgolimab is cost-effective within the Russian healthcare system and allows for increased patient coverage without additional budget expenditures.

  • Open Access

    Divozilimab in neuromyelitis optica spectrum disorders: one-year interim analysis of the AQUARELLE clinical trial

    by Alexey N. Boyko, Mariya N. Zakharova, Taras O. Simaniv, Zoya A. Goncharova, Nikolay N. Spirin, Natalia A. Totolyan, Klara Z. Bakhtiyarova, Irina V. Greshnova, Vyacheslav A. Dudin, Denis S. Korobko, et al.

    Introduction. Divozilimab, a humanized, afucosylated monoclonal antibody that targets CD20, has been approved to treat multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD), and systemic sclerosis. The AQUARELLE clinical trial evaluates the efficacy and safety of divozilimab in patients with NMOSD. Aim. The study aimed to evaluate the efficacy and safety of divozilimab during the first year of treatment in patients with NMOSD. Materials and methods. The AQUARELLE open-label clinical trial enrolled 105 patients with NMOSD. All patients received 500 mg of divozilimab via intravenous infusion every 24 weeks. After 1 year of treatment, the following key parameters were evaluated: the annualized relapse rate (ARR), time to first relapse compared to a historical control group (the placebo group from the SakuraStar study), the proportion of patients with confirmed disability worsening (CDW), changes in Expanded Disability Status Scale (EDSS) scores, and safety parameters. Results. The ARR in patients with NMOSD who received divozilimab for one year was 0.104 (95% confidence interval [CI], 0.056–0.193), and 90.5% of patients had no confirmed relapses. The calculated weighted ratio of ARR (90% CI) for divozilimab to the historical placebo (SAkuraStar) was 0.237 (90% CI: 0.084–0.672), demonstrating superiority of divozilimab. The EDSS score remained stable, and no cases of CDW were reported. Adverse events (AEs) were observed in 76% of patients, most of which were mild or moderate in severity. The most common adverse drug reactions were lymphopenia (21%), leukopenia (11.4%), neutropenia (12.4%), and infusion-related reactions (5.7%). No serious adverse reactions were reported. Conclusion. The 1-year interim results of divozilimab therapy in patients with NMOSD from the AQUARELLE clinical trial demonstrate the sustained efficacy of therapy in reducing both the rate and risk of NMOSD relapses. Additionally, the safety profile was consistent with that expected for anti-B-cell therapy.

  • Assessment of the mortality burden of systemic sclerosis in the Russian Federation: results of a systematic review and meta-regression analysis

    by K. V. Sapozhnikov, L. P. Ananyeva, A. M. Lila, L. A. Garzanova, N. A. Sableva, K. A. Katilova, A. A. Lazarev, D. G. Tolkacheva

  • Open Access

    Comparative efficacy and safety of prolgolimab + nurulimab and nivolumab + ipilimumab in the first-line therapy of metastatic or unresectable melanoma: A systematic review and matching-adjusted indirect comparison

    by Alexander A. Fedenko, Mariya V. Sedova, Alina A. Kolomeytseva, Maxim A. Batov, Olga N. Mironenko, Kirill V. Sapozhnikov, Natalia A. Sableva, Andrey A. Lazarev, Daria G. Tolkacheva, Valentina D. Batorova, et al.

    Background. Metastatic and unresectable melanoma is considered as one of the most aggressive oncological diseases with a high mortality rate. In Russia, two first line immunotherapy combinations have been approved: nivolumab plus ipilimumab (NIVO+IPI) and prolgolimab plus nurulimab (PROLGO+NURU). Both regimens use dual immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). However, the lack of direct randomized comparisons between these regimens makes it difficult to choose the optimal first-line therapy. Aim. This analysis evaluated the relative efficacy and safety of PROLGO+NURU versus NIVO 1 mg/kg + IPI 3 mg/kg (NIVO 1 + IPI 3) and NIVO 3 mg/kg + IPI 1 mg/kg (NIVO 3 + IPI 1) in patients with metastatic and unresectable melanoma using matching-adjusted indirect comparisons (MAICs). Materials and methods. A systematic literature review was performed in Embase and PubMed databases. Three phase III randomized controlled trials (RCTs) were included: OCTAVA (PROLGO+NURU, n=135), CheckMate 067 (NIVO 1 mg/kg + IPI 3 mg/kg, n=314), and CheckMate 511 (two regimens: NIVO 1 mg/kg + IPI 3 mg/kg, n=178; NIVO 3 mg/kg + IPI 1 mg/kg, n=180). Individual patient data (IPD) on outcomes and baseline characteristics for PROLGO+NURU were obtained from the OCTAVA trial. For the NIVO + IPI arms, IPD on overall survival (OS) and progression-free survival (PFS) were reconstructed using Guyot’s algorithm from the published Kaplan–Meier curves, and aggregated baseline-characteristic data were extracted. Pairwise unanchored MAICs were performed, weighting on key prognostic factors and effect modifiers: baseline lactate dehydrogenase levels, TNM-defined presence of distant metastasis (M-stage), Eastern Cooperative Oncology Group (ECOG) performance status, BRAF-mutation status, PD-L1 expression 5%, age, and sum of longest diameters of target lesions. To address partial population non-overlap – specifically, the absence of mucosal melanoma and of asymptomatic central-nervous-system metastases (after local control) in OCTAVA – a simulation-based modelling was applied. Efficacy outcomes were analyzed with Cox proportional-hazards regression, and safety outcomes with logistic regression. Results. OS was statistically significantly higher in the PROLGO+NURU arm than in either NIVO 1 + IPI 3 or NIVO 3 + IPI 1 arms: hazard ratio (HR) 0.69 (95% CI 0.47–0.96; p=0.026) in the CheckMate 067 population, HR 0.64 (0.42–0.91; p=0.011) and HR 0.63 (0.41–0.89; p=0.008) – in the CheckMate 511 population versus NIVO 1 + IPI 3 and NIVO 3 + IPI 1 regimens, respectively. Differences in PFS were statistically insignificant. The PROLGO+NURU regimen also demonstrated a more favorable safety profile, with a lower incidence of treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. Conclusion. MAICs results showed that the PROLGO+NURU regimen achieved statistically significant superiority in OS compared with the approved NIVO+IPI regimens in Russia (as of 2025). The PROLGO+NURU combination also displayed a more favorable safety profile, with fewer treatment-related adverse events, including Grade 3–4 events and events led to treatment discontinuation. It should be emphasized that the comparison is indirect and the horizon of the comparison was limited (by about 50 months in CheckMate 511 population and 65 months in CheckMate 067 population). Consequently, the findings should be interpreted cautiously. Further updates incorporating data for the longer follow-up, including real-world data, are recommended.


  • Open Access

    Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders

    by A. N. Boyko, M. N. Zakharova, T. O. Simaniv, V. M. Alifirova, E. G. Arefieva, M. A. Barabanova, Z. A. Goncharova, I. V. Greshnova, N. V. Dorogov, V. A. Dudin, et al.

    Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.


  • Open Access

    Social significance of rheumatic diseases, negative consequences for the health care system and ways of prevention

    by A. M. Lila, M. A. Korolev, I. N. Shchendrigin, K. V. Sapozhnikov, A. A. Lazarev, N. A. Sableva, D. G. Tolkacheva

       Background. Immunoinflammatory rheumatic diseases (IIRDs) are a significant medical and social problem leading to high mortality, disability and economic burden for society. These diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylitis (axSpA), significantly reduce the quality of life of patients and increase the financial burden on healthcare systems.   Objective. The aim of this systematic review is to assess current data on the risk of death in patients with IIRDs and identify factors associated with increased mortality, as well as analyze the effectiveness of biological drugs in reducing this risk.   Materials and methods. The review includes data from multiple clinical trials and meta-analyses covering the period from 2000 to 2021. The analysis was based on data collected from various sources, including national registries, clinical trials and meta-analyses.   Results. The main results show that IIRDs such as RA, PsA and axSpA significantly increase the risk of death compared to the general population (SMR 2.02 1.79; 2.29). Disease activity, smoking and comorbid conditions are key factors increasing the risk of mortality. The use of biological agents in therapy reduces the risk of death compared to no biological therapy(HR 0.52 0.32; 0.86) and compared to methotrexate (HR 0.77 0.60; 0.97). The use of biological agents also reduces the risk of cardiovascular events and the development of dementia.   Conclusions. Early and active use of biological agents can be a significant factor in reducing the negative consequences of IRDs, including mortality and the progression of cardiovascular diseases.   Conclusion. The results of the systematic review may be useful for developing strategies for managing IIRDs and optimizing medical care for patients. The introduction of GIBPs into the treatment of IIRDs can significantly improve the prognosis and quality of life of patients, reducing the risk of mortality and other adverse outcomes.


  • Open Access

    Evidence synthesis in neuromyelitis optica spectrum disorders: modeling a clinical trial based on published data

    by D. G. Tolkacheva, I. V. Fateev, K. V. Sapozhnikov, O. N. Mironenko, A. A. Lazarev, V. D. Batorova, A. A. Porozova, A. V. Zinkina-Orikhan

       Relevance. Optic neuromyelitis spectrum disorders are a severe orphan nosology for which the search for new highly effective therapeutic options is a priority area of medical care. At the same time, due to the nature of this group of diseases, conducting new clinical trials (CT) is significantly complicated not only by the long and complex recruitment of patients and the unethical nature of using a parallel control group without treatment, but also by conducting comparisons with a historical control group or indirect comparisons, for which planning the sample size in the CT for a new therapy option is a separate methodological task.   Objective. The aim of this study was to estimate the power for the analysis of the primary endpoint in the single-arm BCD-132-6/AQUARELLE trial, which was planned to be performed using an adjusted indirect comparison (AIC) of the study drug divosilimab with published data on the placebo group in the randomized N-MOmentum trial.   Materials and methods. Using the data of the studies identified using a systematic search, a meta-regression model was estimated for the dependence of the average annual relapse rate (ARR) on therapy (anti-CD20 or placebo), the assessment horizon, and baseline patient characteristics. According to its results, for the expected BCD-132-6/AQUARELLE population, a 6-month ARR of 0.116 (95 % CI: 0.030–0.212) was predicted for anti-CD20 therapy. Next, a stepwise effective sample size (ESS) simulation was performed in the divosilimab group with power assessment.   Results. The expected ratio of the ARR of divosilimab and placebo at 6 months was 0.117 (90 % CI: 0.045–0.214) with-out weighting and 0.156 (90% CI: 0.050–0.315) after weighting (ESS). The minimum EES required to achieve a power of 90 % when testing the hypothesis of superiority in the ARR at 6 months for divosilimab therapy compared with placebo with a one-sided type I error probability of 0.05 is 35 people.   Conclusion. The obtained results can be used to support the statistical inference of the BCD-132-6/AQUARELLE study.


  • Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the Russian Federation: a systematic review and network meta-analysis

    by M.N. Zakharova, T.O. Simaniv, K.V. Sapozhnikov, D.G. Tolkacheva, V.D. Sokolova, N.A. Sableva, O.N. Mironenko, A.A. Lazarev, T.V. Khimich

    Objective. To compare efficacy of the new drug divozilimab with other second-line treatment options for relapsing remitting multiple sclerosis (RRMS) that have been already included or submitted application to be included into the «14 high-cost nosologies» program in the Russian Federation. Material and methods. We conducted systematic literature review (PROSPERO ID CRD42022310082) and frequentist network meta-analysis of 2-years efficacy of divozilimab and other second-line therapies to treat RRMS. Results. Annualized relapse rate ratio in divozilimab vs fingolimod was 0.4 (95% CI 0.3—0.7), divozilimab vs cladribin 0.5 (95% CI 0.3—0.9), divozilimab vs alemtuzumab 0.7 (95% CI 0.3—1.7), divozilimab vs ocrelizumab 0.7 (95% CI 0.3—1.6), divozilimab vs ofatumumab 0.7 (95% CI 0.4—1.1), divozilimab vs natalizumab 0.4 (95% CI 0.4—1.1) respectively. Divozilimab had the highest SUCRA rank (0.9) while fingolimod had the lowest (0.4). Conclusion. Systematic literature review and network meta-analysis revealed statistically significant superiority of divozilimab over cladribine and fingolimod and absence of statistically significant differences with alemtuzumab, ocrelizumab, ofatumumab and natalizumab in the annual relapse rate during 2 years of treatment.


  • Open Access

    Key features of observational research data preparation for evidence synthesis

    by A. A. Lazarev, K. V. Sapozhnikov, D. G. Tolkacheva, N. A. Sableva

    Relevance. Observational studies (OS) play a key role in the healthcare system because they provide real-world data (RWD). Unlike randomized controlled trials (RCTs), such studies better reflect routine medical practice. This makes them especially valuable for decision-making aimed at improving the quality and accessibility of medical care.The objective of this article was to analyze key points related to OS data preparation derived from RWD for further evidence synthesis. This work was conducted within a review of asymptomatic hyperuricemia (AH) and was intended to lead to the consensus among rheumatologists on the management patterns of patients with AH in the Russian Federation.Materials and methods. This article examined and described the process of preparing OS data for evidence synthesis.Results. The data analysis revealed significant measures of the efficacy and safety of the medical interventions and pivotal aspects of preparing OS data for subsequent evidence synthesis. We employed a number of techniques to overcome discrepancies in the presentation of the included OS data, including subgroup pooling, unloading of mean and standard deviations from medians and quartiles, and the synthesis of mean values in quartiles from a lognormal distribution via multiple replications. Urinary acid levels based on available OS were calculated using the Hunter-Schmidt estimator. Changes in glomerular filtration rate (GFR) across quartiles were pooled in accordance with the sequential Cochrane community approach or recalculated using community delta unloading equations in instances where GFR values fell within the observation time boundaries.Findings. The results confirmed the importance of preparing appropriate OS data for evidence synthesis. OS provides valuable data for practical use when considering clinical factors and evaluating long-term treatment outcomes.Conclusions. Consequently, observational studies and their preparations can provide a more comprehensive and precise understanding of the efficacy of medical interventions and enhance the quality and accessibility of care for all patients.